Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Treace Medical Concepts (TMCI) Shares Outstanding (Diluted Average) (2020 - 2025)

Treace Medical Concepts' Shares Outstanding (Diluted Average) history spans 6 years, with the latest figure at $63.3 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Diluted Average) rose 1.86% year-over-year to $63.3 million; the TTM value through Dec 2025 reached $63.3 million, up 1.86%, while the annual FY2025 figure was $63.3 million, 1.86% up from the prior year.
  • Shares Outstanding (Diluted Average) reached $63.3 million in Q4 2025 per TMCI's latest filing, roughly flat from $63.1 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $63.3 million in Q4 2025 to a low of $43.6 million in Q2 2021.
  • Average Shares Outstanding (Diluted Average) over 5 years is $58.3 million, with a median of $60.9 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding (Diluted Average): soared 30.61% in 2021, then grew 0.9% in 2024.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $48.4 million in 2021, then rose by 14.17% to $55.3 million in 2022, then grew by 10.09% to $60.9 million in 2023, then rose by 2.07% to $62.1 million in 2024, then grew by 1.86% to $63.3 million in 2025.
  • Per Business Quant, the three most recent readings for TMCI's Shares Outstanding (Diluted Average) are $63.3 million (Q4 2025), $63.1 million (Q3 2025), and $63.0 million (Q2 2025).